Certainly raises some serious questions about how well they will be able to market the drug given the safety profile. Imagine they will have the same reimbursement issues that Gilenya has had.
Still looks like BG12 is in first place of the oral MS drugs in late-stage development. Safety profile looked great at ECTRIMS. waiting on CONFIRM results...
Market Data 
Markets 
AI
